Prihlásiť sa Zaregistrujte sa zadarmo

Dlh / vlastný kapitál spoločnosti QSAM Biosciences

Aká je hodnota metriky Dlh / vlastný kapitál spoločnosti QSAM Biosciences?

Hodnota metriky Dlh / vlastný kapitál spoločnosti QSAM Biosciences, Inc. je -3.34

Aká je definícia metriky Dlh / vlastný kapitál?



Dlh / vlastný kapitál (Debt to equity ratio) ukazovateľ vyjadruje pomer vlastného kapitálu a cudzích zdrojov na financovanie majetku spoločnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dlh / vlastný kapitál spoločností v sektore Health Care sektor na OTC v porovnaní so spoločnosťou QSAM Biosciences

Čomu sa venuje spoločnosť QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Firmy s metrikou dlh / vlastný kapitál podobnou spoločnosti QSAM Biosciences